Scientifically, psilocybin was first identified in 1958, by Dr. Albert Hofmann, who also discovered lysergic acid diethylamide (LSD). This substance could be the basis of a revolutionary new therapy for the treatment of depressive disorders. Recent studies show that psilocybin can have amazing effects on neurons.
Psychedelic drugs in general can cause an intense mystical experience, if used in large doses. But in medically controlled small doses (microdosage), they appear to have an effect on neurogenesis, counteracting the symptoms of depression, increasing the size of neurons and improving the connection between brain cells.
Recent studies on psilocybin, an alkaloid in the psychedelic family, have shown that it relieves the symptoms of depression, benefits that are obtained quickly, with only 2-3 microdoses and are maintained for several months.
Thanks to these findings, the Food and Drug Administration granted the status of “revolutionary therapy” for psilocybin found in cultivated strains of magic mushroom spores in the treatment of major depressive disorder and decided to begin intensive clinical trials in this direction.
Studies on mice at Yale University confirmed that the day after psilocybin administration, the number of neural connections increased by 10% and the neurons by an average of 10%. The immediate and lasting growth of connections between neurons is amazing and lasting, which could open a new era in the medical use of psychedelic substances.